Neuropeptide Y and derivates are not ready for prime time in prostate cancer early detection
Neuropeptide Y (NPY) and related peptides have been proposed as promising biomarkers for the diagnosis of prostate cancer by previous immunoassays and immunohistochemical studies. In this study, we evaluated the additional value of NPY and related peptides compared with prostate-specific antigen (PS...
Autors principals: | Maurer, J, Eugster, PJ, Collins, K, Vocat, C, Oke, J, Nicholson, B, Rakauskas, A, Grouzmann, E, Valerio, M |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
Elsevier
2024
|
Ítems similars
-
Neuropeptide Y and Derivates Are Not Ready for Prime Time in Prostate Cancer Early Detection
per: Jonathan Maurer, et al.
Publicat: (2024-08-01) -
Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?
per: Alexander Meisel
Publicat: (2019-12-01) -
Saxagliptin: A potential doping agent? A randomized, double‐blinded, placebo‐controlled, and crossover pilot study in young active men
per: Nicolas Bourdillon, et al.
Publicat: (2022-12-01) -
Biomarkers in early-stage colorectal cancer: ready for prime time?
per: Church, D, et al.
Publicat: (2012) -
REBOA: is it ready for prime time?
per: Jay Doucet, et al.